A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Public ClinicalTrials.gov record NCT04524871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
Study identification
- NCT ID
- NCT04524871
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 518 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Bevacizumab 15 mg/kg Drug
- Tiragolumab Drug
- Tocilizumab Drug
- TPST-1120 Drug
- Tobemstomig 2100 mg Drug
- Bevacizumab 10 mg/kg Drug
- Tobemstomig 600 mg Drug
- Tobemstomig 1200 mg Drug
- ADG126 Drug
- IO-108 1800 mg Drug
- NKT2152 Drug
- IO-108 1200 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2020 (Actual)
- Primary completion
- Jul 30, 2027 (Estimated)
- Completion
- Sep 30, 2027 (Estimated)
- Last update posted
- Sep 3, 2026
2020 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine Medical Center | Costa Mesa | California | 92627 | — |
| City of Hope | Duarte | California | 91010 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| University of California San Diego Medical Center | San Diego | California | 92103 | — |
| University of California San Francisco Cancer Center | San Francisco | California | 94115 | — |
| UCLA Center for East | Santa Monica | California | 90404 | — |
| Cherry Creek Medical Center | Aurora | Colorado | 80045 | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | — |
| UCHealth Cancer Center Pharmacy - Highlands Ranch Hospital | Highlands Ranch | Colorado | 80129-6694 | — |
| Smilow Cancer Hospital at Yale New Haven | New Haven | Connecticut | 06510 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| University of Kentucky - Markey Cancer Center | Lexington | Kentucky | 40536-7001 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Parkland Health & Hospital System | Dallas | Texas | 75235 | — |
| The University of Texas Southwestern Medical Center at Dallas | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04524871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04524871 live on ClinicalTrials.gov.